MannKind finalizes purchase of scPharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Acquisition Details: MannKind Corporation has completed the acquisition of scPharmaceuticals, which is expected to enhance its revenue growth through the innovative therapy FUROSCIX for edema related to chronic heart failure and kidney disease.
Financial Implications: The acquisition, structured as a tender offer at $5.35 per share plus contingent value rights, positions MannKind for an annualized revenue run rate exceeding $370 million by Q2 2025, bolstered by its existing commercial assets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





